Thyroid hormone inactivation in gastrointestinal stromal tumors.

[1]  J. Fletcher,et al.  Thyroid hormone inactivation in gastrointestinal stromal tumors. , 2014, The New England journal of medicine.

[2]  R. Greil,et al.  First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. Larsen,et al.  Thyroid dysfunction from antineoplastic agents. , 2011, Journal of the National Cancer Institute.

[4]  C. Antonescu,et al.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations , 2010, Proceedings of the National Academy of Sciences.

[5]  A. Bianco,et al.  Reawakened interest in type III iodothyronine deiodinase in critical illness and injury , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[6]  A. Bianco,et al.  Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. , 2008, Endocrine reviews.

[7]  C. Stratakis,et al.  Familial gastrointestinal stromal tumors and germ-line mutations. , 2007, The New England journal of medicine.

[8]  J. Desai,et al.  Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors , 2006, Annals of Internal Medicine.

[9]  A. Butte,et al.  Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. , 2000, The New England journal of medicine.

[10]  David G. Watson,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.